AU Patent

AU2020342591A1 — Formulations and treatment methods

Assigned to Camurus AB · Expires 2022-03-03 · 4y expired

What this patent protects

A lipid controlled-release formulation comprising: a) about 30 to about 50 wt% of at least one diacyl glycerol; b) about 30 to about 50 wt% of at least one phosphatidylcholine; c) about 5 to about 15 wt% ethanol; d) about 0.05 to about 0.5 wt% buprenorphine. A method for the trea…

USPTO Abstract

A lipid controlled-release formulation comprising: a) about 30 to about 50 wt% of at least one diacyl glycerol; b) about 30 to about 50 wt% of at least one phosphatidylcholine; c) about 5 to about 15 wt% ethanol; d) about 0.05 to about 0.5 wt% buprenorphine. A method for the treatment of neonatal abstinence syndrome (NAS) in a human infant in need thereof, said treatment involving the steps of: administering a controlled-release formulation containing a dose of at least one opioid to said infant; wherein said controlled-release formulation provides a therapeutically effective amount of the at least one opioid for at least 4 days following administration.

Drugs covered by this patent

Patent Metadata

Patent number
AU2020342591A1
Jurisdiction
AU
Classification
—
Expires
2022-03-03
Drug substance claim
No
Drug product claim
No
Assignee
Camurus AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.